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Estrogen receptor-α (ERα) has central role in hormone-dependent
breast cancer and its ligand-induced functions have been extensively
characterized. However, evidence exists that ERα has functions that
are independent of ligands. In the present work, we investigated the
binding of ERα to chromatin in the absence of ligands and its func-
tions on gene regulation. We demonstrated that in MCF7 breast can-
cer cells unliganded ERα binds to more than 4,000 chromatin sites.
Unexpectedly, although almost entirely comprised in the larger group
of estrogen-induced binding sites, we found that unliganded-ERα
binding is specifically linked to genes with developmental functions,
compared with estrogen-induced binding. Moreover, we found that
siRNA-mediated down-regulation of ERα in absence of estrogen is
accompanied by changes in the expression levels of hundreds of
coding and noncoding RNAs. Down-regulatedmRNAs showed enrich-
ment in genes related to epithelial cell growth and development.
Stable ERα down-regulation using shRNA, which caused cell growth
arrest, was accompanied by increased H3K27me3 at ERα binding
sites. Finally, we found that FOXA1 and AP2γ binding to several sites
is decreased upon ERα silencing, suggesting that unliganded ERα
participates, together with other factors, in the maintenance of the
luminal-specific cistrome in breast cancer cells.
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Estrogen receptor-α (ERα) expression in breast cancer definesthe Luminal A phenotype, which represents the subset of
tumors that are responsive to endocrine treatments. Spontane-
ous or experimentally induced (1) loss of ERα elicits growth
arrest or epithelial to mesenchymal transition in vitro, whereas
estrogen withdrawal from culture media, albeit reducing pro-
liferation rate, has no such effect. These data suggest that loss of
ERα does not equal depletion of estrogen. ERα is a DNA-
binding, ligand-activated transcription factor, but it can be acti-
vated in absence of ligands by diverse mechanisms, especially by
phosphorylation through different pathways, including protein
kinase A, mitogen-activated protein kinases, and others (ref. 2
and references therein). Ligand-independent activity of ERα was
reported by several groups on individual genes (3–5). Genome-
wide ERα binding in the absence of estrogen was also described
in breast cancer cells acquainted with growing in hormone-
depleted media (6–8) and in mouse uterus (9). These data suggest
that ERα may have a wide genomic function in breast cancer cells
independent of its ligands. Estrogen response in breast cancer
cells was extensively characterized in terms of chromatin
binding and gene-expression regulation using both cell lines and
human tumor biopsies. In vitro models were especially useful
because they allowed correlating ERα-binding events, which are
rarely located at gene promoters, with gene-expression data (10–
13). In these studies, the experimental setting, together with the
fact that breast cancer cell lines show a high grade of genomic
rearrangements (14), made it difficult to evaluate ERα binding in
cells treated with vehicle alone. As a consequence, most authors
have dismissed the question of hormone-independent binding as
compromised peak calling or as unspecific background (15, 16).
However, especially for the clinical problem concerning the re-
sponse to aromatase inhibitors, identifying possible ERα geno-
mic actions in the absence of ligands would be very relevant. In
this work, we first identified bona fide genomic ERα binding sites
in the absence of estrogen in breast cancer cells. We then eval-
uated the effect of ERα silencing on gene transcription and
binding of pioneer factors, demonstrating that ERα controls ge-
nomic activity by binding to several chromatin sites independently
of estrogen exposure. Thus, unliganded ERα may participate,
together with other factors, in the definition of the chromatin
landscape of hormone-dependent breast cancer cells.
Results
Unliganded ERα Cistrome in MCF7 Cells. To identify ERα binding in
the absence of estrogen, MCF7 cells were maintained in hor-
mone-depleted (HD) medium, transfected with control (siCTR)
or ERα-specific (siERα) siRNA and subjected to chromatin
immunoprecipitation followed by high-throughput sequencing
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(ChIP-seq) using antibodies against ERα or IgG as control.
Analysis of ERα enrichment over IgG in siCTR conditions evi-
denced 4,232 unliganded ERα binding sites (apo-ERα binding
sites, aERBS) (P < 1e-05). These sites were almost entirely
contained in the ERα cistrome reported in MCF7 cells cultured
in full medium (FM-ERBS) or after 17β-estradiol (E2) treatment
(E2-ERBS) (Fig. 1A) (15, 17). Accordingly, aERBS showed ge-
nomic distribution similar to estrogen-induced events, with in-
creased prevalence of intergenic location (Fig. S1A).
To verify the specificity of the signal, we examined how siERα,
which reduced ERα protein level by 80% (Fig. S1B), affected
these binding events. ChIP signal was strongly reduced upon
ERα knockdown (Fig. 1B and Fig. S1C), confirming that these
are bona fide ERBS in the absence of hormone. Comparison of
ERα binding enrichment in siCTR over siERα allowed ranking
aERBS by significance (Fig. 1B) and this unraveled diversity
among aERBS. Analysis of top 25% aERBS revealed a higher
average number of reads and a full estrogen-response element
(fERE) as the most represented motif at peak center (63% fERE-
positive, P < 6.2e-58), compared with bottom 25% (27% fERE-
positive, P < 3.9e-07). Bottom aERBS presented a half-ERE as
the most represented motif (Fig. 1C). In addition to this finding,
distribution around the peak center of the fERE probability was
also different in top and bottom peaks (Fig. 1D). Moreover, the
calculated theoretical fERE affinity was significantly higher in top
aERBS (Fig. 1E and Fig. S1D).
Given that aERBS overlap extensively with those observed in
the presence of E2 (Fig. 1A), an important issue is whether aERBS
may represent “residual binding” after estrogen deprival. Using
ChIP-quantitative PCR (qPCR), we verified that apo-ERα binding
to several sites was stable up to 12 d in HDmedium (Fig. S1E), thus
excluding simple estrogen carryover when cells were switched to
HD medium. Furthermore, using GREAT analysis (18), we found
that aERBS lie close to genes associated with development, cell
differentiation, and morphogenesis, whereas E2-ERBS and FM-
ERBS, not in common with aERBS, showed enrichment in me-
tabolism, lipid metabolism and biosynthesis terms (Datasets S1 and
S2). This difference was clearly shown by semantic analysis of the
associated Gene Ontology (GO) terms (19), as shown in Fig. 2A.
Thus, this result suggests that ERα chromatin binding in absence of
hormone has different functions than estrogen-induced binding.
Transcription factor binding sites (TFBS) analysis confirmed
that apo-ERα binding is most likely facilitated by cooperating
factors, as previously shown for liganded ERα (11, 12, 20). aERBS
are frequently accompanied by forkhead box protein A1 (FOXA1/
HNF3A), activating enhancer binding protein 2 gamma (AP2γ/
TFAP2C), glucocorticoid receptor, and other motifs (Fig. 2B, Left).
Interestingly, predicted TFBS were different in the top 25% vs.
bottom 25% aERBS, showing fERE and FOXA1 as the most
enriched motifs, respectively (Fig. S1F). We then compared TFBS
predictions with available ChIP-seq datasets in MCF7 cells (Fig. 2B,
Right). The highest overlap was observed in the case of FOXA1,
GATA binding protein 3 (Gata3), nuclear receptor subfamily 2
group F member 2 (NR2F2), and AP2γ (connecting arcs in Fig.
2B). Noteworthy, FOXA1 and AP2γ binding in HD medium were
among the most overlapped data. As we recently reported for E2-
ERBS (21), aERBS overlap significantly with transposable elements
of the mammalian interspersed repetitive (MIR) and endogenous
retroviral sequence 1 (ERV1) superfamilies (Fig. S1G), which have
been proposed as tools to coevolve TFBS modules.
To investigate the relevance of the aERBS identified in our
study, we performed comparative analyses with ERBS reported
in other available datasets (Fig. S1H and Dataset S3A). First we
verified significant overlap with datasets of MCF7 (15, 22), T47D
(22), and H3396 cells (23) cultured in HD medium, which was
particularly consistent for the top 25% aERBS. We then in-
vestigated whether aERBS are conserved in cells adapted to
long-term estrogen deprival (LTED cells). This analysis showed
extremely variable overlap, from 84.9% in MCF7:2A (7), to al-
most none (0.32%) in other MCF7-derived LTED cell line (6),
suggesting that alternative pathways contribute to adaptation to
hormone deprivation. We also observed significant overlap with
ERBS reported in hydroxy-tamoxifen (OH-T)–treated MCF7
cells in two studies (11, 17), as well as in OH-T–resistant MCF7-
derived clones (Fig. S1 H and I) (11, 24). Semantic analysis of
GO terms comparing ERBS described in OH-T–treated MCF7
cells (15), MCF7:2A LTED cells (7), and aERBS, showed again
a clear association of aERBS with developmental terms (Fig.
S1J). Interestingly, we found that 420 of the aERBS described in
our study were present in the set of 484 ERBS identified in human
breast tumor samples (24), further emphasizing the role of aERBS
in breast tumor cells (Fig. S1H). Noteworthy, among those sam-
ples, 264 overlapping peaks were in top 25% aERBS, whereas
only 27 were in the bottom 25%.
Taken together, these results demonstrate that ERα is bound to
chromatin in absence of hormone to sites that represent a func-
tionally significant subset of estrogen-induced binding sites.
aERBS Are Functional Sites. Individual ChIP-qPCR analysis of se-
lected aERBS not only confirmed ERα binding in the absence of
estrogen but showed consistent decrease after siERα transfection
(Fig. 3A, blue bars). To rule out residual estrogenic activity in HD
medium, we repeated the experiments in serum-free (SF) medium,
showing essentially similar results (Fig. 3A, orange bars).
The fact that most aERBS overlap estrogen-stimulated ERBS
poses the question of whether these sites are fully occupied by
Fig. 1. (A) Venn diagram of aERBS, FM-ERBS (17), and in E2-treated MCF7
cells (E2-ERBS) (15). (B) Peak intensity heat map of aERBS in a ± 5-Kbp ge-
nomic window. The 4,232 aERBS significantly enriched over IgG (siCTR) are
ranked on P value versus ERα ChIP-seq in siERα-treated cells. (C) Average
read counts for top and bottom quartiles in siCTR and siERα peaks. The
S-logo indicates the most enriched motif in this quartile. (D) Localization
probability of a fERE within 200 bp around the peak center of top 25%
(orange) and bottom 25% (green). (E) Box plot depicting the predicted af-
finity of fERE as in D of the top (orange) and bottom (green) 25% (***P <
0.001; two-tailed unpaired t-test). Black arrow indicates ERα peak center.
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ERα in the absence of hormone. As shown in Fig. 3B, treatment
of cells with E2 for 45 min induced a significant increase of ERα
binding, confirming that these sites presented a low occupancy in
absence of ligands, yet maintained E2-inducibility. We also noted
that induction was less pronounced for peaks having a higher
basal level (see for example FKBP4 and RARA), as previously
reported for the intronic RARA binding site (25).
Next, we asked whether ERα down-regulation affects tran-
scription even in the absence of estrogen. Using qRT-PCR, we
verified that mRNA expression of five of seven genes containing
aERBS was indeed significantly decreased 48 h after siERα
transfection. This down-regulation was also reproduced in SF
medium (Fig. 3C). As expected, E2 treatment caused an increase
in mRNA levels up to ninefold (Fig. 3D and Fig. S2A). However,
we observed no correlation between the level of repression after
siERα and the induction by E2.
We also examined the effects of silencing ERα to a greater
extent by transducing MCF7 cells with an shRNA-expressing
vector in different growth conditions: in the absence of hormone
(HD) versus serum-containing medium (FM) or versus E2 treat-
ment (E2) (Fig. 3D and Fig. S2A). The results obtained indicate
that ERα shRNA significantly impaired the response to E2 treat-
ment. Of note, the mRNA level obtained in ERα-knockdown cells
upon E2 treatment is below the level observed in control cells in
HD medium. Taken together, these data indicate that in the ab-
sence of hormone ERα binds to regulatory sites, where it maintains
basal transcription of its target genes, which can be either stimulated
after ligand administration or repressed upon ERα depletion.
To evaluate the genome-wide effects of ERα depletion on the
transcriptome of MCF7 cells, we performed polyA+ RNA-seq
from cells cultured in absence of estrogen. RNAs were extracted
48 h after transfection of siCTR or siERα. To detect a broad
range of variations in RNA levels we combined two comple-
mentary strategies (SI Materials and Methods). This analysis led
to the identification of 912 differentially expressed (DE) genes
with at least 1.5-fold change (P < 0.05). ERα knockdown in the
absence of hormone elicited both decrease (504 genes) and in-
crease (408 genes) of coding and noncoding transcripts (Fig. 4 A
and B). Even though most DE genes were protein coding (727),
we found evidence of regulation of lncRNA expression, in par-
ticular of lincRNAs (57 genes), antisense transcripts (48 genes),
and pseudogenes (54 genes).
To understand whether transcriptional changes observed upon
ERα knockdown overlap E2-stimulated genes, we compared our
data to seven different public expression datasets from MCF7
cells treated with E2 for 4, 6, and 24 h (Dataset S3B). We found
that 27.6% of the deregulated genes upon ERα knockdown were
E2-regulated genes. Additional comparison with two time-course
expression datasets (12, 26) did not increase this ratio (Fig. S2B).
This analysis showed that ERα silencing causes, on average, a
transcriptional effect with an opposite trend compared to E2-
induction (Fig. 4C), confirming that genes controlled by unli-
ganded ERα are a subset of estrogen-responsive genes. Finally,
we examined two public MCF7 datasets measuring the effect of
hormone withdrawal for 48–72 h (Dataset S3B) and we observed
small overlap, though of coherent sign (Fig. 4C). In our experi-
mental design, the time required for ERα down-regulation (48 h)
accounts for the occurrence of indirect effects, in addition to
primary ERα-mediated regulation. Nevertheless, we cannot ex-
clude that some DE genes may represent, in part, an estrogen-
independent gene expression response to ERα depletion.
Next, we sought to correlate aERBS with gene regulation.
Nineteen percent of down-regulated and 5% of up-regulated
genes had an aERBS within 20 kb from the transcription start
site (TSS) and this ratio increased to 75% and 25%, respectively,
extending the range up to 100 kb. In addition, we compared the
distance from the TSS to the nearest aERBS in down-regulated
vs. up-regulated genes. This analysis showed that aERBS accu-
mulated significantly closer to down-regulated genes compared
to random, whereas up-regulated genes did not (Fig. 4D and Fig.
S2C). Taken together, these observations suggest that down-
regulated genes are directly regulated by apo-ERα binding,
whereas the up-regulated set may contain secondary responders.
Looking for functions of DE genes, pathway analysis (Ingen-
uitySystems) showed “cell death and survival,” “cellular growth
and proliferation,” and “cellular movement” as the most signifi-
cant terms (Fig. S2D). However, unexpectedly, “interferon sig-
naling” was indicated as the top canonical pathway and several
interferon (IFN)-related molecules were predicted as activated
upstream regulators (Dataset S4). This double-faced functional
aspect became clear when we considered DE genes separately.
In fact, all of the immune and IFN-related terms and upstream
Fig. 2. (A) Semantic similarity of GO Biological Process terms enriched by
GREAT (18) in aERBS, FM-ERBS (17), or in E2-treated cells (E2-ERBS) (15). The
heat map (Right) reports the semantic similarity computed between the
following subsets: aERBS in common with FM or E2-treated conditions
(aERBS/FM-ERBS shared; aERBS/E2-ERBS shared); ERBS detected in FM or E2
only (FM-ERBS only; E2-ERBS only); aERBS not present in FM or E2 (aERBS
only/not E2-ERBS and aERBS only/not FM-ERBS). The three most represented
GO categories for each cluster are indicated on the left. (B) Circos plot of
TFBS predictions versus ChIP-seq datasets overlap relative to aERBS. Left heat
map (red scale): predicted TFBS matrix frequency. Right heat map (blue
scale): fraction of aERBS overlapped to TFBS reported by ChIP-seq. TFBS and
ChIP-seq datasets characterized by the highest similarity are connected by
lines of increasing color intensity, proportional to matrix similarity. Veh,
untreated; E2, estrogen-treated; FM, full medium.
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regulators were confined to up-regulated genes. Conversely, down-
regulated genes showed cellular growth, survival, proliferation,
development, and cell-cycle functions, together with the expected
“tamoxifen,” “estradiol,” and “ESR1”, as most scored upstream
regulators (Fig. S2 E–G and Dataset S4). This function was clear-
cut among down- and up-regulated genes and was confirmed by
gene-set enrichment analysis (27) (Dataset S5A).
Taken together, these results suggest that unliganded ERα
controls directly a set of genes related to cell growth and
survival and to the maintenance of the epithelial phenotype.
Conversely, depletion of apo-ERα induces a stress-like response
in the cell that is underpinned by the activation of immune and
inflammatory-related genes. This idea was further confirmed by
isolating DE genes possessing an aERBS within 100 kbp from
the TSS. Noteworthy, functions associated with cell proliferation,
death, migration, and invasion were segregated specifically
to aERBS proximal genes (Fig. S2 H and I and Datasets S4
and S5A).
Unliganded ERα Binding Sites Function in Breast Cancer Cells. To
appreciate phenotypic and epigenetic changes induced by ERα
depletion, we used MCF7 cells cultured in HD medium and
transduced with an shRNA-expressing vector, leading to a stable
ERα down-regulation (Fig. S3A). Depletion of ERα completely
stopped cell growth in HD medium (Fig. 5A) and triggered
a mesenchymal-like morphology (Fig. 5B), as previously reported
(1, 5). Decreased apo-ERα binding and mRNA expression of
target genes (Fig. 3D and Figs. S2A and S3B) was accompanied
by increased level of the Polycomb-dependent histone modifi-
cation H3K27me3 at ERα binding sites (Fig. 5C and Fig. S3C),
although we were not able to detect the occupancy of Polycomb
components by ChIP at these sites. As described above, several
TFBS accompany the ERE in aERBS, in particular AP2γ and
FOXA1, which are considered pioneer factors and whose bind-
ing is a necessary prerequisite for ERα function (11, 20). As
expected, we observed that down-regulation of either AP2γ or
FOXA1 reduced apo-ERα binding to aERBS, as reported for
E2-induced binding (20) (Fig. S3D). In contrast to previous
reports (11), FOXA1 siRNA, as well as AP2γ siRNA, reduced in
part ERα protein level (Fig. S3 E and F). Contrary to expect-
ations, though, we observed that ERα silencing resulted in
marked decrease of FOXA1 and dramatic decrease of AP2γ
occupancy in HD medium (Fig. 5 D and E). AP2γ is an ERα-
dependent gene (28) and it is able to stabilize the binding of
FOXA1 at colocalized ERBS (20). AP2γ expression decreases as
a consequence of ERα silencing (Fig. 5F). To exclude the pos-
sibility that the decrease of FOXA1 occupancy reflected AP2γ
down-regulation, we investigated additional aERBS not pos-
sessing AP2γ binding sites. We observed that in this case as well,
markedly decreased apo-ERα binding (Fig. 5G) was followed by
a decrease in FOXA1 occupancy (Fig. 5H), despite the absence
of AP2γ binding at these sites (Fig. 5I).
Taken together, these data demonstrate that unliganded ERα is
an essential factor for the maintenance of the luminal epithelial
cistrome in unstimulated MCF7 breast cancer cells.
Fig. 3. ChIP-qPCR analysis of ERα target genes (A)
following siCTR or siERα transfection, in HD and in
SF medium; (B) after treatment with vehicle (NT) or
10 nM E2 for 45 min (E2). GAPDH promoter was
used as a negative control region (Neg). (C) qRT-PCR
mRNA analysis of target genes in HD and SF me-
dium. Values are shown as ratios of relative mRNA
level in siERα versus siCTR treated cells. (D) qRT-PCR
mRNA analysis of TFF1 and FMN1 after siERα trans-
fection or shERα transduction in HD, FM, and 10 nM
E2 treatment in HD (E2). Error bars represent the SD
of three independent biological replicates.
Fig. 4. (A) Genome-browser view of examples of DE protein coding (TFF1
and TF53INP1) and noncoding genes (H19 and RP11-428L9.2.1) after siCTR or
siERα transfection. Only the main gene isoform is shown. (B) Fraction of up-
regulated and down-regulated genes upon ERα silencing. C, coding genes;
NC, noncoding genes. (C) Heat map representation of the overlap between
DE genes (column A) and seven microarray gene expression datasets in E2-
treated MCF7 cells (columns B–H) and two datasets in MCF7 switched to HD
medium for 48 (column I) and 72 h (column J). Details of each dataset are
reported in Dataset S3B. (Right) Relative effect of siERα vs. E2-effect, calcu-
lated as siERα Log2FC minus median Log2FC of E2-treated datasets. (D) Box
plot distribution of the distance between the TSS of the DE genes and the
closest aERBS center, compared with 1,000 random gene sets. (***P < 0.001;
two-tailed unpaired t test). Down, down-regulated; Up, up-regulated; Rd,
random genes.
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Discussion
Previous work has exhaustively described chromatin binding of
ERα in the presence of ligands and its effects on gene regulation
(10–13, 15). Here, we report an unexpected role of ERα in breast
cancer cells in the absence of estrogen. Unliganded ERα binding
sites represent a nonrandom subset of the estrogen-induced cis-
trome, which is connected with developmental functions. Moreover,
unliganded ERα contributes to transcriptional activity, because its
down-regulation causes changes in gene expression and chromatin
modifications. Finally, we show that depletion of ERα in the ab-
sence of estrogen leads to a reduced binding of pioneer factors, such
as FOXA1 and AP2γ, to shared enhancers. This is an unexpected
feature of ERα, whose binding to chromatin is thought to depend
hierarchically from pioneer factors binding (29–31).
Genome-wide binding of ERα in the absence of hormones was
observed previously in breast cancer (15, 22, 23) and recently in
mouse uterus (9). Interestingly, we found that these sites, mostly
located at enhancer regions, do not represent a random selection of
high-affinity sites. In fact, the functions connected with aERBS
neighboring genes are fundamentally related to cell development
and differentiation that is strongly reminiscent of the primary action
of ERα during development (32). In contrast, the analysis of ERBS
specific for the estrogen treatment highlights the role of ERα in
metabolic regulation, which is in agreement with the physiological
action of estrogen on many tissues. To our knowledge, there was no
previous support to differential functions of ERα in breast cancer
cells, depending on the presence or absence of hormones.
The analysis of the transcriptome upon depletion of ERα
allowed us to unveil the unexpected function of unliganded-ERα
as modulator of specific loci. Indeed, we found that siERα down-
regulated genes often present an aERBS, whereas those that are
up-regulated do not, thus suggesting that the latter might be
affected through an indirect mechanism. Our data suggest that
unliganded-ERα contribute to enhancer activity, granting basal
transcription of neighboring genes that are functionally related
to cellular proliferation and development. In contrast, up-regu-
lated genes are linked to different functions, in particular to the
IFN/inflammatory response, most likely representing an indirect
response to ERα ablation, in line with the protective role of ERα
in several tissues (2). Interestingly, a similar signature can be
observed also in data obtained during long-term hormone dep-
rivation (8) (Dataset S5B). Almost 30% of the siERα-regulated
genes in HD medium was present among E2-responsive genes,
further supporting the observation that aERBS represent a sub-
set of the ERα-regulated cistrome.
We observed that stable ERα silencing by shRNA transduction
induced complete growth arrest. This finding is consistent with
the transcriptional program controlled by unliganded ERα. In
similar conditions, establishment of cells with a complete epi-
thelial to mesenchymal transition has been reported (1), mirror-
ing the invasive phenotype of breast tumor cells escaping ERα
control in vivo. Genes controlled by unliganded ERα are not
only related to cell growth, but several functional terms linked to
the maintenance of the epithelial phenotype were also present.
For example, the MIST1 transcription factor-encoding gene
(BHLHA15), which is repressed 2.1-fold by siERα, is required to
maintain mammary gland differentiation in transgenic mice (33).
One important point in the context of antiestrogen treatments
in breast cancer is whether aERBS are conserved in cells
acquainted with estrogen deprivation (LTED). When we com-
pared our aERBS dataset with those reported in two previous
studies using LTED cell lines, we found that the overlap was
almost complete in MCF7:2A (7) but null in the LTED cells
reported by Miller et al. (6). Noteworthy, this latter case main-
tains a proliferative response to estrogen, whereas the former
does not. It is conceivable that in the latter case the unliganded
ERα cistrome has been widely reprogrammed (6), but ERα
activity is maintained on (some) genes linked to the pro-
liferative response. In contrast, in the former case, unliganded
ERα is possibly fully activated by other endogenous factors (e.g.,
coactivator amplification) as a main growth-sustaining axis.
Noteworthy, GO terms analysis demonstrated that in LTED
ERα is connected to metabolic functions, similarly to E2- or
OH-T–induced sites but in contrast to aERBS.
Most aERBS colocalize with other TFBS. Extensive overlap
with public ChIP-seq datasets confirmed that these sites are in-
deed composite enhancers, possibly evolved from extensive spread
of transposable elements in mammals (21). Significantly, top fac-
tors comprise FOXA1 and AP2γ, known as “pioneer factors” for
sex-steroid receptors (i.e., factors that open the chromatin allow-
ing the landing of nuclear receptors on DNA) (29–31). We con-
firmed that silencing of these factors also reduces unliganded ERα
Fig. 5. (A) Growth curves of MCF7 cells transduced with control shRNA
(black line) or ERα shRNA (gray line) maintained in HD medium. (B) Mor-
phological changes occurring in MCF7 cells after ERα silencing. (C) ChIP
analysis of H3K27me3 at selected aERBS (*P < 0.05, **P < 0.01; one-tailed
paired t test). (D and E) ChIP analysis of FOXA1 (D) and AP2γ (E) as above. (F)
Western blot analysis of ERα, FOXA1 and AP2γ proteins. αtub, α-tubulin:
loading control. (G–I) ChIP analysis of ERα (G), FOXA1 (H), and AP2γ (I) at
selected aERBS predicted to contain FOXA1 binding but not AP2γ bind-
ing sites. Intg1, -2, -3: anonymous intergenic aERBS. For ChIP experi-
ments, GAPDH promoter was used as negative control (Neg). For all of
the experiments shown (B–I), MCF7 cells transduced with shCTR or shERα
were cultured for three days in HD medium before analysis. Error bars
are SD of three independent biological replicates. (Magnification: B, 10×.)
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occupancy. Unexpectedly, we observed that ERα silencing brought
about a reduction of either AP2γ or FOXA1 binding at several
loci, although not completely. The full interpretation of these
results is complicated by the observation that AP2γ transcription is
directly controlled by ERα (28) and its level is reduced in shRNA-
transduced cells. However, we detected a reduction of FOXA1
binding also at enhancers that do not contain AP2γ, in contrast to
previous data (34). A possible reason for this discrepancy is the use
of stable, rather than transient, ERα silencing used in our study.
The data presented here may in part argue against the concept
of pioneer factors as primary drivers of nucleosome remodeling,
leading to ERα binding. Indeed, the elegant demonstration of
progesterone receptor binding to nucleosome PRE, recently pub-
lished (35), further challenges this view. Our results are consistent
with a model where ERα, in the absence of estrogen stimulation,
collaborates with other transcription factors to maintain the lu-
minal epithelial enhancer landscape. When one of these factors is
suppressed, enhancers progressively collapse, also because of the
coordinated decrease of expression of other transcription factors.
It is important to note, in this scenario, that a feed-forward loop
exists involving AP2γ and ERα, which sustain each other’s ex-
pression in breast cancer cells (28, 36).
Ligand-independent functions of ERα have been described in
several tissues in addition to breast cancer cells (2–5). Results
reported here provide a frame to understand why ERα is required to
respond to aromatase inhibitors in breast cancer. Luminal epithelial
cancer cells are stable and survive until ERα is present. The absence
of estrogen keeps these cells growing at a very low rate that is
presumably controlled by the host. Loss of ERα exposes the cells to
immune control, removes a brake on reprogramming, which results,
in vivo, in the emergence of other growth-sustaining pathways.
Materials and Methods
Detailed protocols are provided in SI Materials and Methods.
SiRNA and shRNA Interference. Cells were transfected with siERα (Stealth RNAi
Invitrogen), siAP2γ (Qiagen), siFOXA1 (Santa Cruz), and siCTR (Invitrogen).
Transfection was performed using Lipofectamine 2000 (Invitrogen). MCF7
cells were infected with control shRNA (MISSION shRNA; Sigma-Aldrich) or
shRNA against ERα (MISSION shRNA; Sigma-Aldrich) and selected with 2 μg/mL
puromycin for 3 d.
ChIP and ChIP-Seq. ChIP was performed as previously described (37, 38).
Antibodies and PCR primers used in this assay are reported in SI Materials
and Methods. For ChIP-seq, library preparation for sequencing was per-
formed starting with 10 ng of immunoprecipitated DNA (GAIIX, Illumina).
RNA-Seq. RNA-seq libraries were prepared from poly(A)+ selected, gel-
purified > 200 bp RNA. Sequencing was performed on Illumina HiSeq2000.
Bioinformatic Analysis. Published algorithms were used to analyze ChIP-seq
and gene expression datasets. Ingenuity pathway analysis (IngenuitySystems)
was used for gene ontological analysis. ChIP-seq and RNA-seq data are ac-
cessible in the Gene Expression Omnibus database (accession no. GSE53533).
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